Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary targeted radiotherapies for the treatment of cancer. Headquartered in Austin, Texas, the company leverages its Radiopharma Development Platform to design and manufacture precision radiation agents that selectively deliver radioactive isotopes directly to tumor sites. By harnessing both beta and alpha emitting isotopes, Plus Therapeutics seeks to address a range of solid tumors and hematological malignancies with the potential for improved safety and efficacy profiles compared to conventional treatments.
The company’s lead product candidate, radioprava™ (90Y silicate microspheres), is designed for selective internal radiation therapy of primary liver cancer (hepatocellular carcinoma) and liver metastases. Radioprava is currently being evaluated in multiple clinical trials, and Plus Therapeutics has initiated patient enrollment at centers across North America and Europe. In addition, the proprietary OctreoPharm® platform utilizes 177Lu-labeled somatostatin analogues to target neuroendocrine tumors, while Radspherin® (212Pb) is being explored for the treatment of peritoneal cancers through the delivery of alpha particle therapy directly into the peritoneal cavity.
Founded in 2014, Plus Therapeutics has built a multidisciplinary team with expertise in radiochemistry, oncology, medical physics, and regulatory affairs. The company’s manufacturing operations include a Good Manufacturing Practice (GMP) facility that enables on-site isotope production and radiopharmaceutical formulation. Strategic partnerships with leading academic institutions and contract development organizations support the execution of clinical studies and the advancement of investigational radiotherapies.
Under the leadership of President and Chief Executive Officer Oliver P. Scherzer and Chief Financial Officer Todd A. Vasiloff, Plus Therapeutics is committed to expanding its pipeline through internal discovery and potential collaborations. With a global clinical footprint and a robust intellectual property estate, the company aims to bring novel targeted radiation therapies to patients with limited treatment options and to establish new standards in the management of solid tumors and disseminated cancers.
